Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 182 across all filing types
Latest filing 2024-03-29 Earnings Release
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
NFL BIOSCIENCES: 2023 FULL-YEAR BUSINESS AND EARNINGS UPDATE
Earnings Release Classification · 95% confidence The document is titled '2023 FULL-YEAR BUSINESS AND EARNINGS UPDATE' and contains detailed financial tables (balance sheet, income statement) for the fiscal year 2023. It provides a comprehensive overview of the company's business activities, clinical trial progress, and financial performance. While it mentions that the full annual report will be published later, this document itself contains the substantive financial data and management analysis required for an Earnings Release (ER) or a summary of annual results. Given the detailed financial tables and the nature of the update, it fits the Earnings Release category. FY 2023
2024-03-29 English
NFL BIOSCIENCES : ACTIVITÉS & RÉSULTATS ANNUELS 2023
Annual Report Classification · 95% confidence The document is titled 'NFL BIOSCIENCES : ACTIVITÉS & RÉSULTATS ANNUELS 2023'. It provides a comprehensive overview of the company's annual activities, clinical trial progress, governance changes, and includes a summary table of financial statements (balance sheet and income statement) for the fiscal year ending December 31, 2023. While it functions as an earnings release, it contains substantive financial data and management analysis for the full fiscal year, fitting the definition of an Interim/Quarterly Report (IR) or Annual Report (10-K) context. Given the comprehensive nature of the report covering the full year's results and financial position, it is classified as an Annual Report (10-K). FY 2023
2024-03-29 French
NFL BIOSCIENCES PRÉSENTERA LES RÉSULTATS DE L’ÉTUDE PRECESTO LORS DU CONGRÈS DE LA SRNT, LA SOCIÉTÉ SCIENTIFIQUE DE RÉFÉRENCE AU NIVEAU MONDIAL DANS LA LUTTE CONTRE LE TABAGISME
Regulatory Filings Classification · 95% confidence The document is a press release announcing that NFL Biosciences will present study results (PRECESTO study) at the SRNT (Society for Research on Nicotine & Tobacco) international congress. It details the study's findings, mentions other ongoing studies (CESTO 2), and provides company background. This type of announcement, focusing on scientific presentation schedules and key study updates outside of mandatory periodic financial filings (like 10-K or IR), fits best under a general 'Regulatory Filing' or 'Investor Presentation' category. Since it is an announcement about presenting scientific data at a conference, and not the presentation itself (IP) or a formal financial report, it is most appropriately classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if the focus was heavily on strategic outlook. Given the nature of the announcement (presenting results at a scientific congress), RNS serves as the best general regulatory announcement category when a more specific one like 'ER' or 'IR' is not applicable. The document length (3834 chars) is short enough that it could be an RPA, but it contains substantial news content rather than just announcing a report's availability. Therefore, RNS is the most suitable fallback for this specific scientific/corporate update.
2024-02-13 French
NFL BIOSCIENCES WILL PRESENT THE RESULTS OF THE PRECESTO CLINICAL STUDY AT THE SRNT CONFERENCE, THE WORLD'S LEADING SCIENTIFIC SOCIETY IN THE FIELD OF NICOTINE AND TOBACCO RESEARCH
Regulatory Filings Classification · 95% confidence The document is a press release announcing that NFL Biosciences will present results from the PRECESTO clinical study at the SRNT conference. It details scientific findings, ongoing trials (CESTO 2), and company background. This type of announcement, which communicates scientific or operational updates outside of mandatory financial reporting periods (like 10-K or ER), fits best under the general 'Regulatory Filings' category (RNS) as it is an official, non-financial corporate communication, or potentially an 'Investor Presentation' (IP) if it were the presentation itself, but since it is an announcement *about* a presentation, RNS is the most appropriate general regulatory announcement code. Given the context of scientific updates and conference presentations, RNS serves as the best fit among the provided options for a general corporate update that isn't a formal financial report or management change.
2024-02-13 English
NFL BIOSCIENCES: SUCCESS OF THE STUDY WITH THE CEA
Regulatory Filings Classification · 96% confidence The document is a press release from NFL BIOSCIENCES announcing the successful demonstration of a disruptive new mechanism of action for its drug candidate NFL-101 for smoking cessation, based on a molecular imaging study conducted by the CEA. It details scientific findings, quotes executives and researchers, and mentions ongoing and future clinical trials (CEST0, PRECESTO, CESTO 2). This content is characteristic of an announcement of scientific/research progress rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). Since it is a detailed announcement of scientific progress and development updates, it fits best under the general category of Investor Presentation (IP) or potentially Regulatory Filings (RNS) if it were a mandatory disclosure. Given the detailed scientific nature and the intent to strengthen the project's positioning for potential partners, 'Investor Presentation' (IP) is the most appropriate classification for this type of detailed, forward-looking scientific update aimed at investors, even though it is presented as a press release. It is not a short announcement of a report being available (RPA/RNS).
2024-01-30 English
NFL BIOSCIENCES : SUCCÈS DE L’ÉTUDE AVEC LE CEA
Earnings Release Classification · 95% confidence The document is a press release from NFL Biosciences announcing the successful results of a molecular imaging study conducted with the CEA regarding their drug candidate NFL-101 for smoking cessation. It details scientific findings, quotes management and researchers, and mentions ongoing clinical trials (CEST0 2 results expected July 2024). This type of announcement, focusing on scientific progress, study results, and strategic updates, is characteristic of an Earnings Release (ER) or a general press release that doesn't fit a more specific category like a formal financial report (10-K, IR) or a specific regulatory filing (DIV, DIRS). Since it announces key results and progress, it aligns best with an Earnings Release (ER) which often includes operational and scientific highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the content is a detailed scientific update intended for investors and the public, and it is not a transcript (CT) or a formal quarterly report (IR), ER is the most appropriate fit for a significant operational/scientific update, although RNS is a possibility if this was a mandatory disclosure not covered elsewhere. However, since it details scientific success and progress, it functions similarly to an earnings update highlighting key achievements. Given the options, and the nature of a press release detailing significant operational/scientific progress, ER is chosen over the general RNS fallback, as ER often encompasses key operational achievements beyond just quarterly numbers. FY 2024
2024-01-30 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.